This sponsored webinar provides an overview of the impact and burden of Hepatitis C virus in the US, treatment landscape, elimination progress, access restrictions and the health economics of curative treatment.
AMCP welcomes the introduction of the Equitable Community Access to Pharmacist Services Act of 2023. This legislation would help improve health equity and combat public health threats.
March 2023 Legislative & Regulatory Briefing: The Access to Prescription Digital Therapeutics Act of 2023 is Introduced; Member Benefit! Monitor COVID-19 PHE Guidance with Regulatory NewsBREAKs; AMCP Submits Comments on CMS Advance Notice for 2024; AMCP Joins Pharmacy Organizations in Letter on the COVID-19 PHE; AMCP Comments on Proposed Rule Regarding Interoperability and Prior Authorization.
Health care expert Fred Goldstein sits down with Melissa Andel, principal and founder of CommonHealth Solutions, to discuss the long-awaited launch of Humira biosimilars and what Amgen’s pricing strategy means for patients and payers.
Sanchita Galgalikar, MBA, BS, will serve as the 2023–2024 Executive Fellow in Health Care Association Leadership. This year-long training program provides a rich, in-depth learning experience for pharmacists interested in health care association leadership or managed care pharmacy.
On March 10, AMCP submitted comments to CMS regarding a Notice of Proposed Rulemaking (NPRM) on Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children’s Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges, Merit-Based Incentive Payment System (MIPS) Eligible Clinicians, and Eligible Hospitals and Critical Access Hospitals. AMCP's comments address whether CMS should consider policies to require payers to include information about prior authorizations for drugs on the Patient Access API, the Provider Access API, and the Payer-to-Payer API and how information on the APIs might interact with existing prior authorization requirements.
AMCP applauds the introduction of the Access to Prescription Digital Therapeutics Act of 2023 into the Senate and House by a bipartisan group of Senators and Representatives. The bill would authorize coverage of prescription digital therapeutics by Medicare and Medicaid, helping millions of Americans receive innovative care to treat a growing range of conditions and illnesses.